Topics

Amgen's early-stage studies of MCL-1 inhibitors paused due to cardiac safety signal https://www.firstwordpharma.com/node/1666088  $AMG

06:46 EDT 13 Sep 2019 | FirstWord Pharma

Amgen's early-stage studies of MCL-1 inhibitors paused due to cardiac safety signal https://www.firstwordpharma.com/node/1666088 

Original Article: Amgen's early-stage studies of MCL-1 inhibitors paused due to cardiac safety signal https://www.firstwordpharma.com/node/1666088  $AMG

NEXT ARTICLE

More From BioPortfolio on "Amgen's early-stage studies of MCL-1 inhibitors paused due to cardiac safety signal https://www.firstwordpharma.com/node/1666088  $AMG"

Quick Search

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...